Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Eisai Inc.
ClinicalTrials.gov Identifier:
NCT00658528
First received: April 9, 2008
Last updated: June 30, 2014
Last verified: March 2010
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2010
  Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
No publications provided by Eisai Inc.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):